Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
3
×
boston
clinical trials
gene therapy
new york blog main
san diego blog main
san francisco blog main
third rock ventures
acetylon pharmaceuticals
ally bridge group
ambys medicines
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
cell therapy
constellation pharmaceuticals
deals
diabetic nephropathy
duchenne muscular dystrophy
dyne therapeutics
eventide asset management
facioscapulohumeral muscular dystrophy
focal segmental glomerulosclerosis
genentech
goldfinch bio
holger willenbring
ipo
irving investors
jay ghosh
jeffrey tong
What
diseases
3
×
medicines
3
×
biotech
drug
genetic
ipo
new
ago
aiming
ambys
analysis
big
bio
biotechs
bring
company
considering
control
data
deadly
deal
debuted
develop
dyne
early
employing
expected
experimental
eyes
formed
future
goldfinch
having
humans
ipos
kidney
later
launch
lead
liver
Language
unset
Current search:
medicines
×
diseases
×
" national top stories "
×
biotech
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?